Sugi Predict

Sugi Predict / Compounds / SCHEMBL15652975

SCHEMBL15652975

SCHEMBL15652975

N#CC[C@H](C1CCN(c2cccc(Cl)n2)C1)n1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 2/20 1.00
▸ TYRO3 Q06418 2/20 1.00
▸ JAK2 O60674 14/20 0.74
▸ JAK1 P23458 13/20 0.74
▸ JAK3 P52333 3/20 0.67
▸ DAPK3 O43293 2/20 0.67
▸ PAK4 O96013 2/20 0.67
▸ ABL1 P00519 2/20 0.67
▸ RET P07949 2/20 0.67
▸ LTK P29376 2/20 0.67
▸ CSNK1A1 P48729 2/20 0.67
▸ CLK2 P49760 2/20 0.67
▸ TNK2 Q07912 2/20 0.67
▸ ROCK1 Q13464 2/20 0.67
▸ DYRK1A Q13627 2/20 0.67
▸ IKBKE Q14164 2/20 0.67
▸ NTRK3 Q16288 2/20 0.67
▸ NTRK2 Q16620 2/20 0.67
▸ LRRK2 Q5S007 2/20 0.67
▸ TAOK1 Q7L7X3 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860531 1.00 AXL (1.00) AXLTYRO3JAK2JAK1JAK3
SCHEMBL15653497 1.00 AXL (1.00) AXLTYRO3JAK2JAK1JAK3
SCHEMBL30819103 1.00 AXL (1.00) AXLTYRO3JAK2JAK1JAK3
SCHEMBL29379941 1.00 AXL (1.00) AXLTYRO3JAK2JAK1JAK3
SCHEMBL30008920 1.00 AXL (1.00) AXLTYRO3JAK2JAK1JAK3
SCHEMBL860564 0.92 AXL (0.84) AXLTYRO3JAK2JAK1JAK3
SCHEMBL859327 0.89 AXL (0.81) AXLTYRO3JAK2JAK1JAK3
SCHEMBL859535 0.89 AXL (0.80) AXLTYRO3JAK2JAK1JAK3
SCHEMBL13058316 0.89 AXL (0.80) AXLTYRO3JAK2JAK1JAK3
SCHEMBL3765087 0.89 AXL (0.80) AXLTYRO3JAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501409-A2 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR Incyte Holdings Corporation (US) 2025-02-05 — — EP claimed
US-20240091234-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS INCYTE CORPORATION 2024-03-21 — — US claimed
US-20210093638-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS INCYTE CORPORATION 2021-04-01 — — US claimed
CN-111494386-A Treatment of B cell malignancies by combination of JAK and PI3K inhibitors 因赛特公司 2020-08-07 — — CN claimed
US-9334274-B2 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-05-10 — — US claimed
US-20160000795-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS INCYTE CORPORATION (US) 2016-01-07 — — US claimed
US-20140221379-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2014-08-07 — — US claimed
EP-2432555-B1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORP (US) 2014-04-30 — — EP claimed
EP-3801533-B1 DOSING REGIMEN FOR THE TREATMENT OF PI3K RELATED DISORDERS INCYTE CORP (US) 2026-03-04 — — EP disclosed
US-20250129079-A1 SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR INCYTE CORPORATION 2025-04-24 — — US disclosed
US-20250129098-A1 BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS INCYTE HOLDINGS CORPORATION 2025-04-24 — — US disclosed
US-12226418-B2 Dosing regimen for the treatment of PI3K related disorders INCYTE CORPORATION (US) 2025-02-18 — — US disclosed
EP-4501409-A2 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR Incyte Holdings Corporation (US) 2025-02-05 — — EP disclosed
US-12024522-B2 Salts and processes of preparing a PI3K inhibitor INCYTE CORPORATION (US) 2024-07-02 — — US disclosed
WO-2015184305-A1 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 INCYTE CORPORATION (US) 2015-12-03 — — WO disclosed
US-20150342952-A1 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 INCYTE CORPORATION (US) 2015-12-03 — — US disclosed
WO-2015157257-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR INCYTE CORPORATION (US) 2015-10-15 — — WO disclosed
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2015-09-03 — — US disclosed
US-20150065447-A1 SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS INCYTE CORPORATION (US) 2015-03-05 — — US disclosed
WO-2015026818-A1 SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS INCYTE CORPORATION (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000795-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS JAK2, JAK1, BTK AXL 889/4885TYRO3 280/4885JAK2 1/4885
US-12024522-B2 Salts and processes of preparing a PI3K inhibitor PIK3CD, PIK3CA, PIK3CG AXL 486/4885TYRO3 515/4885JAK2 75/4885
US-20150065447-A1 SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS JAK2, STAT3, IL6 AXL 589/4885TYRO3 326/4885JAK2 1/4885
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885JAK2 2/4885
US-20150342952-A1 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 JAK1, JAK2, MCL1 AXL 1833/4885TYRO3 947/4885JAK2 2/4885
US-20250129079-A1 SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR PIK3CD, PIK3CA, PIK3CG AXL 486/4885TYRO3 515/4885JAK2 75/4885
US-20250129098-A1 BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3R1 AXL 470/4885TYRO3 306/4885JAK2 38/4885
US-12226418-B2 Dosing regimen for the treatment of PI3K related disorders PIK3CA, PIK3CD, PIK3R5 AXL 3245/4885TYRO3 2477/4885JAK2 128/4885
US-20210093638-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS JAK2, JAK1, BTK AXL 889/4885TYRO3 280/4885JAK2 1/4885
US-20240091234-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS JAK2, JAK1, BTK AXL 889/4885TYRO3 280/4885JAK2 1/4885
US-20140221379-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 AXL 449/4885TYRO3 25/4885JAK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.